Celldex Therapeutics CLDX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's operating income?
- Celldex Therapeutics (CLDX) reported operating income of -$84.44M in Q1 2026.
- How has Celldex Therapeutics's operating income changed year-over-year?
- Celldex Therapeutics's operating income decreased by 34.6% year-over-year, from -$62.74M to -$84.44M.
- What is the long-term trend for Celldex Therapeutics's operating income?
- Over 4 years (2021 to 2025), Celldex Therapeutics's operating income has grown at a 41.7% compound annual growth rate (CAGR), from -$71.24M to -$287.37M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.